Eli Lilly and Company (NYSE: LLY) unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $485 price target.
Cantor Fitzgerald maintained Eli Lilly (NYSE:LLY) $485 price target Read Post »
Morgan Stanley analyst David Phung maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $448 to $445.
Morgan Stanley lowered Eli Lilly (NYSE:LLY) price target to $445 Read Post »
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $444 to $448.
Morgan Stanley raised Eli Lilly (NYSE:LLY) price target to $448 Read Post »
Jefferies analyst Akash Tewari maintains Eli Lilly (NYSE:LLY) with a Hold and raises the price target from $290 to $310.
Jefferies raised Eli Lilly (NYSE:LLY) price target from $290 to $310 Read Post »
Eli Lilly announced Wednesday that a 70 percent price cut for its two best-selling insulin products, Humalog and Humulin, will take effect in the fourth quarter. Lilly also said it would reduce the list price of unbranded insulin from $82 to $25 per vial starting May 1, the lowest price for insulin taken by diabetics at mealtime and lower than Lilly’s 1999 Humalog sticker price. Eli Lilly also plans to improve a program that limits out-of-pocket costs to $35 a month for patients.
Eli Lilly cuts insulin drug prices by 70% Read Post »